| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Merger transaction costs | 0 | 0 |
| Net cash provided by financing activities | 27,130 | 26,532 |
| Net increase in cash, cash equivalents, and restricted cash | 5,127 | 17,450 |
| Cash and cash equivalents at beginning of period | 20,272 | - |
| Cash and cash equivalents at end of period | 25,399 | - |
LENZ Therapeutics, Inc. (LENZ)
LENZ Therapeutics, Inc. (LENZ)